These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2008152)

  • 1. Developmental toxicity of valproic acid.
    Cotariu D; Zaidman JL
    Life Sci; 1991; 48(14):1341-50. PubMed ID: 2008152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valproic acid in pregnancy: how much are we endangering the embryo and fetus?
    Ornoy A
    Reprod Toxicol; 2009 Jul; 28(1):1-10. PubMed ID: 19490988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Species differences in pharmacokinetics and drug teratogenesis.
    Nau H
    Environ Health Perspect; 1986 Dec; 70():113-29. PubMed ID: 3104022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teratogenic potential of valproic acid.
    Hanold KC
    J Obstet Gynecol Neonatal Nurs; 1986; 15(2):111-6. PubMed ID: 3084732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting the human teratogenic potential of the anticonvulsant, valproic acid, from a non-human primate model.
    Mast TJ; Cukierski MA; Nau H; Hendrickx AG
    Toxicology; 1986 May; 39(2):111-9. PubMed ID: 3085290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic evaluation of various metabolites and analogs of valproic acid: teratogenic potencies in mice.
    Nau H; Löscher W
    Fundam Appl Toxicol; 1986 May; 6(4):669-76. PubMed ID: 3086174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valproic acid-induced placental and teratogenic effects in rats.
    Khera KS
    Teratology; 1992 Jun; 45(6):603-10. PubMed ID: 1345037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Structural bases of the teratogenic effects of the antiepileptic valproic acid. 2-n-propyl-4-pentenic acid, the first structural analogue with significantly higher teratogenic action than VPA].
    Hauck RS; Nau H
    Naturwissenschaften; 1989 Nov; 76(11):528-9. PubMed ID: 2515442
    [No Abstract]   [Full Text] [Related]  

  • 9. Hydroxamic acid and fluorinated derivatives of valproic acid: anticonvulsant activity, neurotoxicity and teratogenicity.
    Gravemann U; Volland J; Nau H
    Neurotoxicol Teratol; 2008; 30(5):390-4. PubMed ID: 18455366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myo-inositol enhances teratogenicity of valproic acid in the mouse.
    Massa V; Wlodarczyk B; Giavini E; Finnell RH
    Birth Defects Res A Clin Mol Teratol; 2006 Mar; 76(3):200-4. PubMed ID: 16511884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic determinants of embryotoxicity in rats associated with organic acids.
    Scott WJ; Collins MD; Nau H
    Environ Health Perspect; 1994 Dec; 102 Suppl 11(Suppl 11):97-101. PubMed ID: 7737049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of teratogenicity of trans-2-ene-valproic acid compared to valproic acid in rats.
    Vorhees CV; Acuff-Smith KD; Weisenburger WP; Minck DR; Berry JS; Setchell KD; Nau H
    Teratology; 1991 Jun; 43(6):583-90. PubMed ID: 1882349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valproic acid developmental toxicity and pharmacokinetics in the rhesus monkey: an interspecies comparison.
    Hendrickx AG; Nau H; Binkerd P; Rowland JM; Rowland JR; Cukierski MJ; Cukierski MA
    Teratology; 1988 Oct; 38(4):329-45. PubMed ID: 3149039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teratogenicity and developmental toxicity of valproic acid in rats.
    Vorhees CV
    Teratology; 1987 Apr; 35(2):195-202. PubMed ID: 3110992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developmental toxicity and structure-activity relationships of aliphatic acids, including dose-response assessment of valproic acid in mice and rats.
    Narotsky MG; Francis EZ; Kavlock RJ
    Fundam Appl Toxicol; 1994 Feb; 22(2):251-65. PubMed ID: 8005377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new model for embryotoxicity testing: teratogenicity and pharmacokinetics of valproic acid following constant-rate administration in the mouse using human therapeutic drug and metabolite concentrations.
    Nau H; Zierer R; Spielmann H; Neubert D; Gansau C
    Life Sci; 1981 Dec; 29(26):2803-14. PubMed ID: 6799722
    [No Abstract]   [Full Text] [Related]  

  • 17. Structure-metabolism relationships (SMR) for the prediction of health hazards by the Environmental Protection Agency. II. Application to teratogenicity and other toxic effects caused by aliphatic acids.
    Di Carlo FJ; Bickart P; Auer CM
    Drug Metab Rev; 1986; 17(3-4):187-220. PubMed ID: 3105990
    [No Abstract]   [Full Text] [Related]  

  • 18. Anticonvulsant profile and teratogenic evaluation of potent new analogues of a valproic acid urea derivative in NMRI mice.
    Okada A; Noyori H; Yagen B; Shimshoni JA; Bialer M; Fujiwara M
    Birth Defects Res B Dev Reprod Toxicol; 2009 Oct; 86(5):394-401. PubMed ID: 19830722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teratogenic effects of dosage levels and time of administration of carbamazepine, sodium valproate, and diphenylhydantoin on craniofacial development in the CD-1 mouse fetus.
    Eluma FO; Sucheston ME; Hayes TG; Paulson RB
    J Craniofac Genet Dev Biol; 1984; 4(3):191-210. PubMed ID: 6438150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teratogenic valproic acid concentrations: infusion by implanted minipumps vs conventional injection regimen in the mouse.
    Nau H
    Toxicol Appl Pharmacol; 1985 Sep; 80(2):243-50. PubMed ID: 3927520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.